Extract
Asthma is the most common long-term respiratory condition, affecting more than 300 million people worldwide and, despite concerted efforts to achieve disease control and reduce exacerbations, it claims approximately 1000 lives each day [1]. The health and financial burdens associated with asthma are increasing, both at individual and population levels. A recent study estimated the annual cost of asthma in the USA to be more than USD 80 billion, taking into account direct medical costs, mortality and loss of attendance at school and work [2].
Abstract
Inadequate assessment of adherence to maintenance medication leads to loss of power and increased costs in trials of severe asthma therapy http://bit.ly/2USoiQU
Footnotes
Conflict of interest: C.N. McBrien has attended an international conference with Boehringer Ingelheim and a national meeting with TEVA.
Conflict of interest: A. Menzies-Gow reports grants, personal fees, non-financial support and other (research conducted in the author's institution and consultancy agreement) from AstraZeneca, personal fees from Novartis, personal fees and non-financial support from Teva, personal fees and other (consultancy agreement) from Vectura, personal fees and other (research conducted in the author's institution) from GlaxoSmithKline, personal fees, non-financial support and other (research conducted in the author's institution) from Boehringer Ingelheim, personal fees and other (consultancy agreement) from Sanofi, and personal fees from Hoffman La Roche, outside the submitted work.
- Received March 25, 2019.
- Accepted April 3, 2019.
- Copyright ©ERS 2019